<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536391</url>
  </required_header>
  <id_info>
    <org_study_id>GO29868</org_study_id>
    <nct_id>NCT02536391</nct_id>
  </id_info>
  <brief_title>Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of Ipatasertib (GDC-0068) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This Phase I, open-label, randomized, 3-period crossover study was designed to determine the
      relative bioavailability of ipatasertib administered as capsule and tablet formulations to
      healthy volunteers. In addition, the influence of food on ipatasertib exposure will also be
      determined. Participants will be randomized to one of six treatment sequences to receive
      three treatments of a single oral administration of ipatasertib in, 1) tablet formulation in
      the fasted state, 2) capsule formulation in the fasted state or 3) tablet formulation in the
      fed state. Pharmacokinetics will be assessed, and standard physical and clinical evaluations
      will be performed throughout the study. Time on study is expected to be 3 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Ipatasertib</measure>
    <time_frame>Days 1, 8 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (tmax) of Ipatasertib</measure>
    <time_frame>Days 1, 8 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) from Hour 0 to the Last Quantifiable Concentration (AUC0-t) of Ipatasertib</measure>
    <time_frame>Days 1, 8 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) from Hour 0 Extrapolated to Infinity</measure>
    <time_frame>Days 1, 8 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-Life (t1/2) of Ipatasertib</measure>
    <time_frame>Days 1, 8 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Clearance (CL/F) of Ipatasertib</measure>
    <time_frame>Days 1, 8 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Ipatasertib</measure>
    <time_frame>Days 1, 8 and 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From check in (Day -1) to 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Sequence 1: Tablet/Capsule/Tablet with food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: Tablet/Tablet with food/Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib capsule administered after fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3: Capsule/Tablet/Tablet with food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4: Capsule/Tablet with food/Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib tablet administered after fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5: Tablet with food/Tablet/Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib capsule administered after fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6: Tablet with food/Capsule/Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib (capsule)</intervention_name>
    <description>Orally administered single dose of Ipatasertib formulated as a capsule.</description>
    <arm_group_label>Sequence 1: Tablet/Capsule/Tablet with food</arm_group_label>
    <arm_group_label>Sequence 2: Tablet/Tablet with food/Capsule</arm_group_label>
    <arm_group_label>Sequence 3: Capsule/Tablet/Tablet with food</arm_group_label>
    <arm_group_label>Sequence 4: Capsule/Tablet with food/Tablet</arm_group_label>
    <arm_group_label>Sequence 5: Tablet with food/Tablet/Capsule</arm_group_label>
    <arm_group_label>Sequence 6: Tablet with food/Capsule/Tablet</arm_group_label>
    <other_name>GDC-0068 (capsule)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib (tablet)</intervention_name>
    <description>Orally administered single dose of Ipatasertib formulated as a tablet.</description>
    <arm_group_label>Sequence 1: Tablet/Capsule/Tablet with food</arm_group_label>
    <arm_group_label>Sequence 2: Tablet/Tablet with food/Capsule</arm_group_label>
    <arm_group_label>Sequence 3: Capsule/Tablet/Tablet with food</arm_group_label>
    <arm_group_label>Sequence 4: Capsule/Tablet with food/Tablet</arm_group_label>
    <arm_group_label>Sequence 5: Tablet with food/Tablet/Capsule</arm_group_label>
    <arm_group_label>Sequence 6: Tablet with food/Capsule/Tablet</arm_group_label>
    <other_name>GDC-0068 (tablet)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females, between 18 and 55 years of age, inclusive

          -  Body mass index between 18.5 and 29.9 kg/m^2, inclusive

        Exclusion Criteria:

        - Clinically significant findings from medical history or screening evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

